Acoustic Assay Launched to Increase Productivity of Protein Analyses
|
By LabMedica International staff writers Posted on 03 Jun 2014 |

Image: Highly Sensitive Next Generation Acoustic Assays in Complex Sample Matrices (Photo courtesy of Bioscale).
A new, six-plate cartridge format for Acoustic Assays was launched that will enable larger, cost efficient protein analysis studies.
BioScale, Inc., (Lexington, MA, USA) launched a new, six-plate cartridge format for its Acoustic Assays to enable larger protein analysis studies, with unprecedented cost efficiency. The product enhancement, for use on the Bioscale's proprietary ViBE instrumentation platform, will be introduced at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego (CA, USA) which will take place during November 2–6, 2014.
Christopher Silva, vice president, commercial operations at BioScale said, "Our ViBE platform, paired with our nonoptical Acoustic Assays, overcomes limitations of traditional methods like ELISA or Western blot by providing a simple, highly sensitive method of measuring specific proteins in a complex sample, with walk-away automation. This enables fast assay development—that takes days, rather than months." Mr. Silva added, "Now, our new six-plate format enables even larger studies—providing up to 576 data points in one cartridge—at a cost as low as only USD 2 per sample well. This will be particularly important for scientists needing to study cell signaling pathways and biomarkers […]."
BioScale's ViBE platform enables nonoptical, acoustic protein measurement utilizing BioScale's proprietary Acoustic Membrane MicroParticle (AMMP) Acoustic Membrane MicroParticle technology. The company's Acoustic Assays measure analyte concentration by determining changes in oscillation frequency caused by the binding of microparticles to the sensor surface. To date, the platform featured 1-, 2- and 3-plate cartridge formats allowing up to 288 samples per cartridge. Now, the six-plate format allows up to 576 individual data points in a single assay or the reuse of the cartridge for multiple assays for up to 576 measurements across 5 days.
The ViBE platform is a novel protein measurement technology enabling highly sensitive, automated Acoustic Immunoassays to accelerate drug discovery, development and production of biological and pharmaceutical products. The sensitivity, precision, and walk-away capabilities of our non-optical AMMP technology enables customers to achieve breakthrough advancements in protein research that were not previously attainable via traditional ELISA, Western blot and IHC methods, allowing ultra-sensitive detection of proteins in complex biological samples. The company's instrumentation platform is used by leading biopharmaceutical companies, academic institutions and government laboratories.
Related Links:
BioScale, Inc.
BioScale, Inc., (Lexington, MA, USA) launched a new, six-plate cartridge format for its Acoustic Assays to enable larger protein analysis studies, with unprecedented cost efficiency. The product enhancement, for use on the Bioscale's proprietary ViBE instrumentation platform, will be introduced at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego (CA, USA) which will take place during November 2–6, 2014.
Christopher Silva, vice president, commercial operations at BioScale said, "Our ViBE platform, paired with our nonoptical Acoustic Assays, overcomes limitations of traditional methods like ELISA or Western blot by providing a simple, highly sensitive method of measuring specific proteins in a complex sample, with walk-away automation. This enables fast assay development—that takes days, rather than months." Mr. Silva added, "Now, our new six-plate format enables even larger studies—providing up to 576 data points in one cartridge—at a cost as low as only USD 2 per sample well. This will be particularly important for scientists needing to study cell signaling pathways and biomarkers […]."
BioScale's ViBE platform enables nonoptical, acoustic protein measurement utilizing BioScale's proprietary Acoustic Membrane MicroParticle (AMMP) Acoustic Membrane MicroParticle technology. The company's Acoustic Assays measure analyte concentration by determining changes in oscillation frequency caused by the binding of microparticles to the sensor surface. To date, the platform featured 1-, 2- and 3-plate cartridge formats allowing up to 288 samples per cartridge. Now, the six-plate format allows up to 576 individual data points in a single assay or the reuse of the cartridge for multiple assays for up to 576 measurements across 5 days.
The ViBE platform is a novel protein measurement technology enabling highly sensitive, automated Acoustic Immunoassays to accelerate drug discovery, development and production of biological and pharmaceutical products. The sensitivity, precision, and walk-away capabilities of our non-optical AMMP technology enables customers to achieve breakthrough advancements in protein research that were not previously attainable via traditional ELISA, Western blot and IHC methods, allowing ultra-sensitive detection of proteins in complex biological samples. The company's instrumentation platform is used by leading biopharmaceutical companies, academic institutions and government laboratories.
Related Links:
BioScale, Inc.
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







